Key result
Recombinant buffalo interferon-α demonstrates antiviral activity up to ~10^6 U/mg in preclinical cell lines.
Recombinant water buffalo IFN-alpha demonstrates significant in vitro antiviral activity, suggesting potential as a biological agent for bovine viral diseases.
Recombinant buffalo IFN-α shows in vitro antiviral activity; leaves open therapeutic potential pending in vivo bovine validation.
Interferon(IFN)-α genes were cloned from genomic DNA of Fuan and Fuzhong water buffaloes by PCR, and the PCR products were inserted into a pQE30 vector to construct recombinant expression plasmids. Sequence analysis showed that both clones were composed of 498 nucleotides, encoding a mature polypeptide with 166 amino acids (aa). They were defined as two new subtypes, with 91.6–94.2% identity at the amino acid level by comparison with eight previously published bovine IFN-α subtypes. Results of SDS-PAGE and Western blotting showed that each of the recombinant proteins was expressed in inclusion bodies inEscherichia coliwith molecular weight of 20 kDa and the recombinant proteins were 25% of the whole proteins. Inclusion bodies were denatured and renatured with urea and the antiviral activities of the recombinant buffalo IFN-α (rBuIFN-α) were 105U/mg and 106U/mg in CEF/VSV and MDBK/VSV cell lines, respectively. Additionally, rBuIFN-α had good effects against challenge byinfectious bovine rhinotracheitis virus. The rBuIFN-α are potential biological agents for the prevention and treatment of various kinds of bovine viral disease.
No takes yet. Share an insight, caveat, or question.
Xi-ju et al. (2005) studied this question. Recombinant buffalo IFN-α (rBuIFN-α) was evaluated on Antiviral activities in CEF/VSV and MDBK/VSV cell lines. Recombinant buffalo interferon-α expressed in E. coli demonstrated antiviral activities of 10^5 U/mg and 10^6 U/mg in CEF/VSV and MDBK/VSV cell lines, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: